A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study

NCT00567710 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: BL - 1020
DRUG: BL - 1020
DRUG: Placebo
DRUG: Risperidone

Sponsor

BioLineRx, Ltd.